Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

Clinical trial NCT06998108 · RECRUITING

Trial details

NCT number: NCT06998108
Sponsor: BeBetter Med Inc
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

HR+/HER2- Locally Advanced, Metastatic Breast Cancer

Start date: 2022-06-09
Primary completion: 2025-12-31
Enrollment: 330

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.